Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07020806 · ClinicalTrials.gov registry record · Phase 1
[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
A Phase 1 study of Metastatic Lobular Breast Carcinoma, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07020806 is a Phase 1 study of Metastatic Lobular Breast Carcinoma that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07020806, a Phase 1 study of Metastatic Lobular Breast Carcinoma, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).
Conditions Studied
Interventions
- DRUG [68Ga]Ga DOTA-5G
Study Locations (1)
California
- University of California Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-11-18 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07020806
The ClinicalTrials.gov registry entry for NCT07020806 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Lobular Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which [68Ga]Ga DOTA-5G is the first listed.
NCT07020806 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07020806 about?
NCT07020806 is a clinical study titled "[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)". This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).
What is the current status of trial NCT07020806?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-11-18. Estimated completion is 2027-06.
What conditions does trial NCT07020806 study?
This clinical trial studies the following conditions: Metastatic Lobular Breast Carcinoma.
What interventions are being tested in trial NCT07020806?
The interventions under investigation include: [68Ga]Ga DOTA-5G (DRUG).
Who is sponsoring clinical trial NCT07020806?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07020806 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Lobular Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.